Aims: To develop a method for evaluating the start of anticoagulation treatment in inpatients. Methods: One hundred case notes were audited using a proforma based on local guidelines in accordance with British Society for Haematology recommendations. Results: Confirmatory investigations were done in 93% and 79% of patients with symptomatic deep venous thrombosis and pulmonary embolism, respectively. Identification of patients' risk factors for anticoagulation by history taking and laboratory tests was often inadequate: baseline coagulation screen, platelet count, liver function and renal function tests were done in 52%, 95%, 70% and 87% of cases, respectively. There was a tendency to undertreat patients: 33% of the activated partial thromboplastin times (APTT) and 58% of the International Normalised Ratios (INR) were subtherapeutic. The heparin-warfarin crossover period was particularly problematic: 37% stopped heparin without an INR that day, or had an INR ofless than 2. Microscopic haematuria was monitored occasionally. Of the 62 patients continuing anticoagulation, 72% were discharged with the final INR in the therapeutic range. At discharge, only
audited using a proforma based on local guidelines in accordance with British Society for Haematology recommendations. Results: Confirmatory investigations were done in 93% and 79% of patients with symptomatic deep venous thrombosis and pulmonary embolism, respectively. Identification of patients' risk factors for anticoagulation by history taking and laboratory tests was often inadequate: baseline coagulation screen, platelet count, liver function and renal function tests were done in 52%, 95%, 70% and 87% of cases, respectively. There was a tendency to undertreat patients: 33% of the activated partial thromboplastin times (APTT) and 58% of the International Normalised Ratios (INR) were subtherapeutic. The heparin-warfarin crossover period was particularly problematic: 37% stopped heparin without an INR that day, or had an INR ofless than 2. Microscopic haematuria was monitored occasionally. Of the 62 patients continuing anticoagulation, 72% were discharged with the final INR in the therapeutic range. At discharge, only 74% of patients had documented appointments for the anticoagulant Clinic, the period between discharge and appointment ranging from 0 to 12 days. Of the 25 cases with an appointment exceeding four days after discharge, only six (24%) had arrangements for an interim INR check. Conclusions: The experience allowed the proforma to become streamlined to a more practical, reliable, and valid tool for use elsewhere. Findings will be fed back to the hospital staff to promote practice improvements before closing the audit loop by re-evaluating practice. Further studies are in progress to identify barriers experienced by doctors in implementing the guidelines and problems in the process of referral to the anticoagulant clinic. (3 Clin Pathol 1993; 46:67-71) Anticoagulants are commonly used in Patients were first identified from the haematology laboratory worksheet if they had had either an isolated APTT or an APTT simultaneous with an INR. They were then entered as cases if it was confirmed when crosschecked with the medical notes that the patient had been treated with heparin. Patients who had heparin prophylactically, including patients already receiving longterm warfarin, were excluded from the study. Inpatient medical notes were retrieved retrospectively for all identified as cases from April to July 1991, and prospectively for such patients from August to October 1991. Retrospective retrieval of inpatient medical notes was achieved by requesting case notes from the medical records department up to five times. Eighty three case notes were requested, for which 79 (95%) were retrieved. Of these, 57 (72%) cases were valid cases and entered into the audit study. Prospective audit of case notes was achieved by obtaining these from medical records, intercepting them when with medical secretaries, on the wards, or at the anticoagulant clinic. All the 63 case notes searched for were successfully retrieved: eight from medical records (six entered the study) and 55 looked for by the research assistant (37 entered the study).
Results

STUDY POPULATION
The 100 audited cases comprised 58 women and 42 men. The age range was 20 to 90 years (median 57 years). The diagnoses for which heparin was given included deep venous thrombosis (n = 40), pulmonary embolism (n = 47), deep vein thrombosis with pulmonary embolism (n = 5), cerebrovascular accident (n = 1), systemic embolus other than cerebrovascular accident (n = 4), pulmonary embolism with systemic embolus (n = 1), cerebrovascular accident with systemic embolus (n = 1), and intracardiac thrombus (n = 1 Case number Therapeutic range Figure 1 APTT results by individual case (days 1-10; n = 60). measured four hours after starting the heparin infusion and daily thereafter. More frequent testing may be necessary, detailed in the guidelines, if heparin control is unsatisfactory. Over the first 10 days of anticoagulation, a total of 439 APTT tests were done on 100 cases, 38% of which were in the therapeutic range (50 to 80 seconds), 33% were below 50 seconds, and 29% above 80 seconds (table 2, fig 1) . The mean APTT calculated for each case who continued anticoagulation ranged from 36 to 109 seconds (mean (SD) 64 (15) seconds).
The hospital guidelines advise doing the first INR check on day 3 of treatment with warfarin. Of the 60 (out of a possible 62) cases where relevant information was not missing or ambiguous, 32 (53%) cases had an INR done before this (10 cases had INR tests on the first day, 29 cases on the second day). Forty four (73%) cases did have the INR tested on the third day of warfarin treatment. During the first 10 days of anticoagulation, 272 INR tests were done for the 62 cases continuing anticoagulation. Only 38% fell in the therapeutic range, 58% below, and 4% above (table 2, fig  2) . Even if we exclude the results of the first three days before warfarin has achieved full effect, of the 186 INR tests done from days 4 to 10 of warfarin treatment, only 50% of tests lay in the therapeutic range, 44% below, and 6% above (table 2, fig 3) . Table 2 It is recommended in the guidelines that heparin be stopped only after the INR equals or exceeds 2-0. Of the 49 cases where relevant information was not missing or ambiguous, 18 (37%) cases stopped heparin without an INR test that day, or had an INR below 2-0. Another recommendation in the guidelines is that the patient should not be discharged until the INR is stable between 2-0 to 4-5. We found that although 72% of the cases were discharged with the final INR in the therapeutic range, 21% were under 2-0 and 7% over 4-5. Monitoring the side-effects of overanticoagulation is important, and it is recommended in the guidelines that this should include the presence of microscopic haematuria, bruising, and bleeding from venepuncture sites or wounds. clinic appointment ranged from 0-12 days (median five days). For six (23%) of the 26 cases with an appointment of four or more days after discharge, a specific arrangement was made to recall the patient to the ward to check the patient's INR during this period.
Discussion
The purpose of anticoagulant treatment is to prevent the development and complications of thrombosis. Ideally, direct outcome measures of practice would include incidence of thromboembolic events and bleeding episodes (which may indicate under-and overanticoagulation, respectively). In designing the audit proforma, however, we encountered great difficulty in incorporating these as criteria, particularly in extracting this information from the inpatient case notes because of inadequate documentation. Hence we had to use proxy measures, such as APTT and INR ranges for anticoagulation control, and microscopic haematuria for over anticoagulation. It is recognised that microscopic haematuria may be of little clinical importance, but we feel that it may alert the clinician to make a more detailed assessment. The value of inpatient medical notes in the audit of clinical practice depends on the completeness and accuracy of these as records of relevant events. In the ideal situation, auditors extracting data from case notes would confidently assume that an unrecorded event did not occur. In reality, we found that many events did occur but were poorly recorded, and therefore could not be audited. Examples include putting thrombo-embolic deterrent (TED) stockings on the patient, switching the heparin pump off temporarily, and discussions with the patient. This has been discussed more fully in other studies,4 and reinforces the importance of meticulous note-keeping, so that audit using medical records is both feasible and reliable.
Another limitation we encountered in auditing medical notes was the difficulty in interpreting certain documented entries. Hence for many interesting aspects of anticoagulant treatment which we had originally incorporated into the audit proforma, the repeatability among auditors was very poor. For example, a barium meal report "crater in greater curvature" was perceived by the medically trained auditor but not by the research assistant as indicative of a previous peptic ulcer. Other examples of audit criteria we were obliged to reject because of this poor reliability as indicators of quality included pre-anticoagulation consideration of other risk factors such as patient compliance, history of oesophageal varices, history suggestive of a bleeding disorder and heparin hypersensitivity); monitoring of bruising and bleeding from venepuncture sites; and the quality of information given to the patient.
Clinical practice should be periodically evaluated against established guidelines. The guidelines themselves should be regularly reviewed and updated in the light of changes in epidemiology, science, and technology. Guidelines on anticoagulation would be useful only if successfully implemented in day-to-day practice by junior hospital doctors. It is fundamental that the guidelines be distributed widely and explained clearly, and reinforced with sufficient educational impetus. A lack of appreciation of the pharmacokinetic properties of anticoagulants may account for several of the suboptimal practices. For example, the patient's risk to being anticoagulated is often inadequately assessed in regard to history taking, weight measurement, enquiry of concurrent medication and investigation of baseline coagulation screen, platelet count, liver function and renal function tests. The regimen for initiating anticoagulants using a bolus dose of heparin was inconsistent, and the monitoring of anticoagulation was often illogical (for example, testing the INR before the third day of warfarin treatment) and inadequate (for example, failure to do urinalysis). It may be that the importance of these practices is not adequately appreciated by medical staff, perhaps from inadequate education.
The control of anticoagulation, as indicated by mean APTT and INR values within the therapeutic range, appears reasonable. However, the high percentage of tests, both APIT and INR, falling below therapeutic range suggests a tendency for underanticoagulation by junior hospital doctors, a finding also noted by Doble and Baron.5 This may also account for the significant proportion of patients discharged with a final INR below therapeutic range. A particularly important period for anticoagulation control is the crossover of heparin with warfarin. Disappointingly, in a third of the cases heparin was stopped without an INR test that day, or when the INR was below 2-0. Schulman et al advocate stopping heparin only when the INR is within the therapeutic range for two consecutive days, indicating that a stable warfarin effect has been achieved. 6 Hospital guidelines may need to incorporate a similar specific recommendation.
The handover of patients from the wards to the anticoagulant clinic is a crucial link in the continuity of anticoagulation care. Having committed a patient to anticoagulation while on the ward, it is imperative that follow up as an outpatient be responsibly arranged. Anticoagulant clinic appointments and INR rechecks should be appropriate and referral adequate. Our findings have provided insight to weaknesses which exist at the point of ward discharge, and we plan to develop a more detailed method of auditing this important process of patient referral.
In this study the audit proforma has been successfully applied at the pilot hospital to evaluate inpatient management of anticoagulant treatment using medical notes. The experience has enabled us to streamline the original proforma to a more practical, reliable, and valid tool. We have begun to feed back the results of this study to the hospital staff, and will close the audit loop by re-evaluating inpatient management with the audit proforma after relevant policy changes to improve areas of substandard practice have been implemented. The audit proforma is available on request.
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